A review of literature

Immunological findings
A possible involvement of the immune system is supported by the observation that the onset of CFS is often preceded by virus infections and a 'flu-like' illness. Among immune disfunctions the decrease either in number or functional activity of natural killer (NK) cells, especially in the number or activation status of CD56+ cells was found by many groups [Brenu EW et al, 2011; Fletcher MA, et al, 2010; Brenu EW et al, 2010; Mihaylova I. et al, 2007; Maher KJ et al, 2005 , Nas K, 2011 . Lorusso L. at al [2009] reported an increased number of CD8+ cytotoxic T lymphocytes; CD38 and HLA-DR activation markers and a decrease in CD11b expression associated with an increased expression of CD28+ T subsets. The reduction in CD16+ and CD57+/CD56+ NK lymphocytes along with an expansion of CD8+/CD56+ and CD16-/CD56+ NK subsets were found in the CFS group by [Tirelli et al, 1994] . Other works also found an increase in CD8+ T-cell numbers [Robertson MJ et al, 2005] while Barker E et al [1994] found no significant differences in the absolute numbers of circulating total T cells (CD3+) and of total helper/inducer (CD4+) or suppressor/cytotoxic (CD8+) T cells. Some papers report a post-vaccination or post-infection onset of CFS. Exogenous insults, such as Lyme disease, infectious mononucleosis, Epstein-Barr virus, enteroviruses, parvovirus, gastric and other infections, vaccinations, exposure to toxins, some stressful life events can lead to CFS [Devanur LD et al, 2006 , Ortega-Hernandez OD et al., 2009 . However a working group of the Canadian Laboratory Center for Disease Control that examined the suspected association between CFS and vaccinations did not find relation of CFS to vaccination [Appel S at al, 2007] .
Immune cells activation
Cell associated adhesion molecules and the level of their soluble forms can be used as activation markers. CD56+ NK cells from CFS subjects were found to express an increased amount of cell adhesion molecules CD11b, CD11c, CD54; and activation antigen CD38 [Tirelli et al, 1994] . CD4+ T lymphocytes from CFS patients displayed an increased expression of the intercellular adhesion molecule-1 (ICAM-1/CD54). The total number of circulating (CD19+) B lymphocytes was higher in CFS patients than in controls [Tirelli U et al, 1994] . Another marker of activation is the production of pro-inflammatory cytokines. Brenu EW et al have studied Th1 and Th2 cytokine profile of CD4+T cells. Compared to healthy individuals, CFS patients displayed significantly increased levels of IL-10, IFN-γ, and TNF-α [Brenu EW et al, 2010 ]. An alteration in cytokine profile was found by many other groups [Patarca R, 2001; Carlo-Stella N et al, 2006; Tomoda A et al, 2005] .
Genomics of CFS
Starting from 2005, a microarray analysis was applied to determine gene expression profiles of CFS patients. The results published differ significantly between research groups [Kaushik N et al, 2005; Fang H et al, 2006; Carmel L et al, 2006; Frampton D et al, 2011] . For example, upregulated expression of ABCD4, PRKCL1, MRPL23, CD2BP2, GSN, NTE, POLR2G, PEX16, EIF2B4, EIF4G1, ANAPC11, PDCD2, KHSRP, BRMS1, and GABARAPL1 was found by Kaushik N et al [2005] . A completely different gene set (PTPRR, DEFB1, FLJ, HSFY1, EST, HPRT1, GUCA1B, CACNG2, ESR2, MOG, DFFA, ACBD6 and 12 others) was identified by www.intechopen.com Fang H et al [2006] . The most recent publication attempted and failed to predict the diagnosis basing on genomic data [Frampton D et al, 2011] . Thus, genes involved in CFS still to be found more accurately. However, most authors conclude that genes responsible for immune cell activation and perturbation of neuronal and mitochondrial functions are involved.
Treatment of CFS patients
In recent decades, many therapies for CFS have been examined including: psychological "cognitive behaviour therapy", gradual physical exercise, pharmacological therapies, which included antibiotics and anti-depressant drugs [Avellaneda FA et al, 2009] . Mild improvements were found in adolescent groups after cognitive behaviour therapy [Smith M et al, 2003 ]. Other approached were not effective [Alegre de Miquel C et al, 2005; Vermeulen&Scholte, 2004; Staud R, 2007 , Romani A et al, 2008 . We want to emphasize that antidepressant medication has been found to have no beneficial effect on improving the symptoms of CFS showing that CFS does not have a dominant psychological aetiology as it was considered for many years [Friedberg & Jason 2001 , Chambers et al. 2006 .
Chronic immune response hypothesis
It can be hypothesized that CFS, at least at its early stages and at least in some CFS patients, results from immune system exhaustion induced by an excessive immune response against widely spread pathogens such as M.tuberculosis or Herpes virus. Mycobacterium tuberculosis (MBT) is the most successful pathogen of mankind and remains a leading cause of death due to a bacterial pathogen. It is estimated that every third person on the planet is infected with MBT. Yet 90-95% of those who are infected with MBT remain otherwise healthy. These people are classified as "latently infected". Mouse studies have shown that susceptibility or resistance to tuberculosis (TB) depends on genetic factors [Kondratieva et al, 2010] . It is also the case for humans. Epidemiological evidence points to a major role of human genetic factors in the development of TB. Numerous genetic studies were conducted with variable results. Some HLA class II alleles and variants of the natural resistance-associated macrophage protein 1 (NRAMP1) gene are most likely involved [Abel&Casanova, 2010 , Stein CM, 2011 . We hypothesize that human population can be divided on genetic basis into three TB groups: i) resistant; ii) susceptible; and iii) intermediate ones. The susceptible group in low pathogen environment is a reservoir from which active TB cases emerge (reactivation TB). Resistant group can control MBT without any signs of infection or immune system activation. While the last one -intermediate group, is resistant to TB for the expanse of immune system exhaust leading to chronic fatigue as one possibility. Rheumatoid arthritis is a disease where cross reactivity to MBT and self heat shock proteins is considered as one of disease onset mechanisms [Adebajo AO et al, 1995] . The risk of tuberculosis is increased 2-to 10-fold in RA patients [Baronnet L et al, 2011] . Cases of joint/bone tuberculosis are reported [Yagi O et al, 2007] . Among pulmonary TB patients 72% show severe to moderate level of anxiety and depression according to Hospital Anxiety and Depression Scale (HADS) [Aamir&Aisha, 2010] . Sore throat or laryngopharyngitis can also be found in TB [Raza&Rahat, 2010; Huon et al, 2009 ]. The coincidence of major CFS signs and TB infection can be continued.
Biomarkers predictive of susceptibility and resistance to TB
Recently whole-blood microarray gene expression analyses were performed in TB patients and in latently as well as uninfected healthy controls to define biomarkers predictive of www.intechopen.com susceptibility and resistance [Maertzdorf J et al. 2011] . Fc gamma receptor 1B was identified as the most differentially expressed gene, and, in combination with four other markers, produced a high degree of accuracy in discriminating TB patients and latently infected donors. Elevated expression of innate immune-related genes in active TB and higher expression of particular gene clusters involved in apoptosis and natural killer cell activity in latently infected donors are likely to be the major distinctive factors determining failure or success in controlling TB. As it was shown above, a decrease in NK cell numbers or their functional activity is the major immune disturbances found in CFS patients. Could it be a connection to TB? [Popova I et al, 2008; Svirshchevskaya E et al, 2008; Ertneeva I et al, 2008; Skripkina P et al, 2008] . These 14 patients were selected on the basis of their deviated immune status. They were asked to fill in two questionnaires: Multidimensional Fatigue Inventory (MFI) and Zung depression scale [Smets EM et al, 1995; Zung, 1971] . For comparison the questionnaires were also filled in by 18 donors with normal parameters of immune cells. MFI and Zung scores demonstrated an increased level of depression and fatigue in 10 out of 14 persons with deviated immune status. The rest 4 had immunodeficiency and chronic infections. All 14 were suggested to take part in a trial aimed to verify our hypothesis. Each patient signed the voluntary consent to take part in the trial. Immunological data of healthy donors were used as a control.
Experimental data
Flow cytometry analysis for surface markers
Peripheral blood lymphocytes (PBL) were isolated on density gradient and washed three times in phosphate buffered saline (PBS). For the fluorescence-activated cell sorter (FACS) analysis cells were transferred to FACS buffer (PBS, 1% bovine serum albumin, 0.05% NaN 3 ). Three-color flow cytometry was performed using FACScan instrument, CellQuest software (BD Biosciences) and the following antibodies: CD3-PE, CD19-FITC, CD4-FITC, CD8-PE, CD16-FITC, CD56-PE, HLA-DR-FITC (all from Sorbent, Moscow). Live events (5,000-10,000) were acquired with propidium iodide exclusion of dead cells.
Treatment
Volunteers with signs of chronic fatigue were suggested the treatment with isoniazid, 300 mg per day during 30 days. Immune status was estimated before and after treatment at days 0, 30, and 90. (Fig.1) . Among 8 volunteers 6 have normal CD4/CD8 ratio during all period of testing (Fig.1) . Patient #5 showed a significant increase in this parameter while patient #8 demonstrated immunodeficiency at 3 d and 4 th testing. Patient #5, a young girl, suffered from seasonal allergy. Patient #8 was asymptomatic. Among total group of donors we have found two types of immune deviations: decrease in CD4/CD8 ratios (<1.2) or NK cell numbers (<5%) was found in 12 persons (12%) and a significant increase in CD4/CD8 (>3) or NK numbers (>20%) was found in 11 volunteers (11%). CD8 subsets or in CD16, CD56 cells. So, we divided the patients into two groups basing on CD4/CD8 ratio. Group 1 included patients with CD4/CD8<1.2 and was designated "immunodeficiency group" (IDG) ( Table 3) . Group 2 included patients with >2.1 and was designated as "hyperstatus group" (HSG) ( Table 4) . We also included CD4/CD16 and CD4/CD56 ratios for comparison. Table 5 shows in the same way as Tables 3-4 summary  from Table 1 for healthy controls. The statistical difference between IDG and HSG is significant for the CD4, CD8 percentage and their ratios only because we have selected patients using CD4/CD8 criteria for division. If we do the same using CD16 differences (low group <12, high group >12) we will also get significant difference, in this case for CD16, CD56 percentage and ratios (Tables 6 and 7 immune parameters of fatigue patients can at least partially explain why no significant difference in comparison with healthy subjects was found by previously published studies. As our patients cannot be diagnosed strictly as CFS patients, we may only hypothesize that either immune abnormalities in CFS patients are overseen or they can be less pronounced during disease progression. ##1, 2, 3, 8) found that they started feeling "better and more energetic" after 2-3 weeks of treatment. Their MFI and ZQ scores were significantly improved. Patient 6 described the effect as "relaxing" and "sleep impoving". Other patients selfrated the effect as neutral however the MFI and ZQ scores on average were better for 8 of 9 patients. Clinical symptoms of other associated pathologies (prostatitis, sore throat, couth, phlegm, flu-like symptoms) subsided to the end of treatment in those patients who had them at the time of the trial. We monitored 8 of 14 patients for 1 year. Two months post-treatment all of them felt significantly better than before with no signs of fatigue. At 6 mo post treatment 2 persons who earlier suffered severe fatigue, again had sings of it and were recommended the second course. The results were the same: quick elimination of fatigue symptoms and slow improvement in somatic symptoms.
Results
Abnormal immune status in some healthy volunteers
Clinical characteristics of fatigue group patients
CD4
Immunological effects of izoniazid treatment
We analyzed parameters of lymphocytes in treated patients before the treatment and at days 30 and 90. The results are shown in Fig.2 . All parameters of immune status were better than before the treatment showing that the therapy was effective. 
Discussion
MTB, the causative agent of tuberculosis remains a major threat to global health as the leading cause of death due to a bacterial pathogen. Every third person on the planet is infected with MBT. However, only 10% among infected individuals develop TB while others remain otherwise healthy. These people are classified as "latently infected," but remain a reservoir of MBT. Latent TB has traditionally been defined as infection with MBT in foci within granuloma that remain in nonreplicating state but retain their ability to induce TB when a disruption of the immune response occurs. However, recent experimental data support a dynamic model of latent TB where endogenous reactivation as well as damage response occur constantly in immunocompetent individuals [Cardona PJ, 2009 , Ahmad S, 2011 . This model suggests that some type of macrophages (foamy macrophages) phagocytose extracellular nonreplicating MBT; however, the bacilli do not grow in the intracellular environment of activated macrophages but are also not killed due to the nonreplicating state of the bacilli. The nonreplicating bacilli-loaded foamy macrophages drain from lung granuloma towards the bronchial tree and return to a different region of lungs and begin the infection process at a new location once again [See review Ahmad S, 2011] . It can be speculated that activated foamy macrophages can enter not only the lungs but also other organs as TB is known in many forms of localization [Horsburgh&Rubin, 2011; Russell, 2011; Dorhoi et al, 2011 , Galimi R, 2011 . These new locations of MBT can attract immune cells inducing all the symptoms characteristic for CFS patients.
Here we put forward a new hypothesis that at least in some patients chronic fatigue can be induced by ongoing immune response against MBT. We have chosen patients from a large cohort of individuals basing on two criteria: i) they have signs of fatigue and depression; and ii) their immune status was deviated from a normal one. Selected patients have various medical problems (prostatitis, herpes, sore throat, couth, phlegm, sinusitis, pharyngitis, mild reumathoid arthritis). The aims of the trial were: i) to estimate whether anti-tuberculosis treatment can help in resolving fatigue and depression; and ii) if the treatment affects immune status of the patients. The results were encouraging as most patients felt a decrease in fatigue symptoms. This effect was not long-lasting as in severe cases 6 mo later some patients again complained the signs of fatigue. The remittance of the disease can again be explained in terms of "chronic interaction between MBT and immune cells". Izoniazid treatment hypothetically removed some active foci inducing a following decrease in immune response. However, new locations of MBT were formed with time due to a genetic susceptibility to TB. This means that anti-tuberculosis treatment could possible be needed for a longer time or for repeated courses during several years.
We have also shown that parameters of immunity were improved after anti-tuberculosis treatment. These results showed that immune status can be used as a parameter to monitor. In our trial only persons with deviated immunity were included. Possibly among CFS patients also individuals with immune disturbances can be considered as candidates for izoniazid therapy. Finally I want to emphasize that the effect of izoniazid on fatigue could be a by-stander to MBT infection and be connected to some other targets in brains of immune system. However, new studies are required to clarify this matter.
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